Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck KGaA, Darmstadt, Germany
With
Merck Serono Limited, UK
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsing Multiple Sclerosis (Relapsing Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis with relapses) according to the Association of British Neurologists criteria (30) in the UK and the revised 2005 McDonald criteria (31) in Ireland
Prescribed Rebif® (22mcg or 44mcg) using the RebiSmart™ injection device
Have been using RebiSmart™ for 24 months and be due a device replacement as part of their standard routine of care
Registered with Bupa Home Healthcare (UK) or SENSE nurse (Ireland)
Be willing to give consent for their adherence data to be captured in the audit
Discontinued Rebif before 24 months of treatment
Unable or unwilling to give consent for their adherence data to be captured in the audit
Clareo Health | An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device
